导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.04% | 1130/4773 |
| 近一周 | -2.00% | 1050/5462 |
| 近一月 | -3.66% | 1892/5421 |
| 近一季 | -6.91% | 2237/5209 |
| 近半年 | 2.70% | 944/4920 |
| 近一年 | 9.90% | 1051/4366 |
| 近两年 | 52.53% | 1407/2954 |
| 近三年 | 36.58% | 818/2253 |
| 成立以来 | 134.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.50% 2327/4961 |
19.14% 1318/5312 |
- - |
- - |
| 2025 | 21.80% 2015/4813 |
-0.32% 2200/3635 |
1.05% 2480/4076 |
18.97% 2213/4524 |
1.63% 1291/4813 |
| 2024 | 13.97% 1087/3463 |
4.29% 462/2808 |
-0.12% 685/3014 |
12.91% 2278/3129 |
-3.10% 2261/3463 |
| 2023 | -7.37% 914/2656 |
3.95% 1086/2280 |
-2.44% 593/2385 |
-2.78% 750/2515 |
-6.04% 1609/2655 |
| 2022 | -23.70% 1159/2207 |
-13.77% 835/1919 |
5.71% 842/2016 |
-15.20% 1242/2113 |
-1.29% 1690/2208 |
| 2021 | -1.82% 821/1822 |
-1.48% 502/1255 |
4.36% 895/1330 |
-6.58% 962/1466 |
2.22% 656/1822 |
| 2020 | 38.14% 367/1250 |
-8.44% 610/1028 |
13.81% 592/1067 |
14.94% 249/1164 |
15.34% 216/1184 |
| 2019 | 43.75% 187/1092 |
27.08% 359/754 |
0.72% 161/804 |
3.91% 227/850 |
8.08% 357/918 |
| 2018 | -19.52% 168/834 |
- - |
- - |
- - |
-11.37% 287/691 |
| 2017 | 26.14% 105/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.68% 162/605 |
- - |
- - |
- - |
- - |
| 2015 | 11.61% 156/575 |
- - |
- - |
- - |
- - |
| 2014 | 47.94% 98/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.74% 131/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.68% 49/140 |
- - |
- - |
- - |
- - |
| 2011 | -24.80% 73/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 浦银安盛沪深300指数增强A VS. 长安沪深300非周期A(740101) |